Malignant stem cells have been identified in acute myelogenous leukemia, chronic myeloid leukemia, and some types of acute lymphoblastic leukemia. Like normal stem cells, these leukemic stem cells (LSCs) are able to self-renew, differentiate, and proliferate extensively. Evidence suggests that LSCs are critical for the initiation and perpetuation of leukemic disease.
Methods
We reviewed the literature describing the characteristic features of LSCs in various leukemias and the novel molecular approaches being used to specifically ablate the LSC population.
Results
Studies have demonstrated the potential importance of ablating LSCs when treating leukemia. The unique characteristics of LSCs that differentiate them from their normal counterparts can be exploited to specifically target the malignant population.
Conclusions
Current therapeutic strategies may not effectively ablate the LSC, leaving the potential for disease progression or relapse. A better understanding of LSC cell and molecular biology will allow the design of more effective therapies.
GriffinJ.D., LowenbergB.Clonogenic cells in acute myeloblastic leukemia. Blood.1986; 68: 1185–1195.
15.
BonnetD., DickJ.E.Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med.1997; 3: 730–737.
16.
HolyoakeT., JiangX., EavesC.Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood.1999; 94: 2056–2064.
17.
GuanY., GerhardB., HoggeD.E.Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood.2003; 101: 3142–3149.
18.
MirroJ.Jr. Pathology and immunology of acute leukemia. Leukemia.1992; 6(suppl 4): 13–15.
19.
LapidotT., SirardC., VormoorJ.A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature.1994; 367: 645–648.
20.
BlairA., HoggeD.E., AillesL.E.Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood.1997; 89: 3104–3112.
21.
BlairA., HoggeD.E., SutherlandH.J.Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR-. Blood.1998; 92: 4325–4335.
22.
BlairA., SutherlandH.J.Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). Exp Hematol.2000; 28: 660–671.
23.
SutherlandH.J., BlairA., ZapfR.W.Characterization of a hierarchy in human acute myeloid leukemia progenitor cells. Blood.1996; 87: 4754–4761.
24.
JordanC.T., UpchurchD., SzilvassyS.J.The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia.2000; 14: 1777–1784.
25.
TerpstraW., PloemacherR.E., PrinsA.Fluorouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture. Blood.1996; 15;88: 1944–1950.
26.
GuzmanM.L., UpchurchD., GrimesB.Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. Blood.2001; 97: 2177–2179.
27.
CohenO., InbalB., KissilJ.L.DAP-kinase participates in TNF-alpha- and Fas-induced apoptosis and its function requires the death domain. J Cell Biol.1999; 146: 141–148.
28.
Levy-StrumpfN., KimchiA.Death associated proteins (DAPs): from gene identification to the analysis of their apoptotic and tumor suppressive functions. Oncogene.1998; 17: 3331–3340.
29.
TamuraT., IshiharaM., LamphierM.S.An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature.1995; 376: 596–599.
30.
KatzenellenbogenR.A., BaylinS.B., HermanJ.G.Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood.1999; 93: 4347–4353.
31.
NarayanG., Arias-PulidoH., KoulS.Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer.2003; 2: 24.
32.
GreenW.B., SlovakM.L., ChenI.M.Lack of IRF-1 expression in acute promyelocytic leukemia and in a subset of acute myeloid leukemias with del(5)(q31). Leukemia.1999; 13: 1960–1971.
33.
OgasawaraS., TamuraG., MaesawaC.Common deleted region on the long arm of chromosome 5 in esophageal carcinoma. Gastroenterology.1996; 110: 52–57.
34.
KaufmannS.H., KarpJ.E., SvingenP.A.Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood.1998; 91: 991–1000.
35.
KonoplevaM., ZhaoS., HuW.The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol.2002; 118: 521–534.
36.
van StijnA., van der PolM.A., KokA.Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leukemia. Haematologica.2003; 88: 497–508.
37.
GuzmanM.L., NeeringS.J., UpchurchD.Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood.2001; 98: 2301–2307.
38.
PyattD.W., StillmanW.S., YangY.An essential role for NF-kappaB in human CD34(+) bone marrow cell survival. Blood.1999; 93: 3302–3308.
39.
RowleyJ.D.Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature.1973; 243: 290–293.
40.
Ben-NeriahY., DaleyG.Q., Mes-MassonA.M.The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science.1986; 233: 212–214.
41.
GroffenJ., StephensonJ.R., HeisterkampN.Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell.1984; 36: 93–99.
42.
FialkowP.J., JacobsonR.J., PapayannopoulouT.Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med.1977; 63: 125–130.
43.
HolyoakeT.L., JiangX., DrummondM.W.Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. Leukemia.2002; 16: 549–558.
44.
VerfaillieC.M., McCarthyJ.B., McGlaveP.B.Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia: decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type I V. J Clin Invest.1992; 90: 1232–1241.
45.
UdomsakdiC., EavesC.J., SwolinB.Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc Natl Acad Sci U S A.1992; 89: 6192–6196.
46.
SirardC., LapidotT., VormoorJ.Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. Blood.1996; 87: 1539–1548.
47.
WangJ.C., LapidotT., CashmanJ.D.High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood.1998; 91: 2406–2414.
48.
EavesC., CashmanJ., EavesA.Defective regulation of leukemic hematopoiesis in chronic myeloid leukemia. Leuk Res.1998; 22: 1085–1096.
49.
HolyoakeT.L., JiangX., JorgensenH.G.Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood.2001; 97: 720–728.
50.
JiangX., LopezA., HolyoakeT.Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci U S A.1999; 96: 12804–12809.
51.
CobaledaC., Gutierrez-CiancaN., Perez-LosadaJ.A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood.2000; 95: 1007–1013.
52.
GeorgeA.A., FranklinJ., KerkofK.Detection of leukemic cells in the CD34(+)CD38(-) bone marrow progenitor population in children with acute lymphoblastic leukemia. Blood.2001; 97: 3925–3930.
53.
BuchdungerE., CioffiC.L., LawN.Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther.2000; 295: 139–145.
54.
DrukerB.J., LydonN.B.Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest.2000; 105: 3–7.
55.
GrahamS.M., JorgensenH.G., AllanE.Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood.2002; 99: 319–325.
56.
HoltzM.S., SlovakM.L., ZhangF.Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood.2002; 99: 3792–3800.
57.
BhatiaR., HoltzM., NiuN.Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood.2003; 101: 4701–4707.
58.
KiyoiH., NaoeT., YokotaS.Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia.1997; 11: 1447–1452.
59.
KiyoiH., TowatariM., YokotaS.Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia.1998; 12: 1333–1337.
60.
YokotaS., KiyoiH., NakaoM.Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia.1997; 11: 1605–1609.
61.
CareR.S., ValkP.J., GoodeveA.C.Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol.2003; 121: 775–777.
62.
GillilandD.G., GriffinJ.D.The roles of FLT3 in hematopoiesis and leukemia. Blood.2002; 100: 1532–1542.
63.
GariM., GoodeveA., WilsonG.c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol.1999; 105: 894–900.
64.
Abu-DuhierF.M., GoodeveA.C., CareR.S.Mutational analysis of class III receptor tyrosine kinases (C-KIT, C-FMS, FLT3) in idiopathic myelofibrosis. Br J Haematol.2003; 120: 464–470.
65.
TraxlerP.Tyrosine kinases as targets in cancer therapy: successes and failures. Expert Opin Ther Targets.2003; 7: 215–234.
66.
FabbroD., RuetzS., BuchdungerE.Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther.2002; 93: 79–98.
67.
TseK.F., MukherjeeG., SmallD.Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia.2000; 14: 1766–1776.
68.
ZhangS., FukudaS., LeeY.Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med.2000; 192: 719–728.
69.
FrankD.A.StAT signaling in cancer: insights into pathogenesis and treatment strategies. Cancer Treat Res.2003; 115: 267–291.
70.
MeshinchiS., StirewaltD.L., AlonzoT.A.Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood.2003; 102: 1474–1479.
71.
BosJ.L., Verlaan-de VriesM., van der EbA.J.Mutations in N-ras predominate in acute myeloid leukemia. Blood.1987; 69: 1237–1241.
72.
FarrC., GillR., KatzF.Analysis of ras gene mutations in childhood myeloid leukaemia. Br J Haematol.1991; 77: 323–327.
73.
SebtiS.M., HamiltonA.D.Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene.2000; 19: 6584–6593.
74.
MilellaM., EstrovZ., KornblauS.M.Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood.2002; 99: 3461–3464.
75.
MilellaM., KornblauS.M., EstrovZ.Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest.2001; 108: 851–859.
76.
CountouriotisA., MooreT.B., SakamotoK.M.Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. Stem Cells.2002; 20: 215–229.
77.
StadtmauerE.A.Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Curr Oncol Rep.2002; 4: 375–380.
78.
GilesF.J.Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia. Expert Rev Anticancer Ther.2002; 2: 630–640.
79.
KordesU., KrappmannD., HeissmeyerV.Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia.2000; 14: 399–402.
80.
BargouR.C., EmmerichF., KrappmannD.Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest.1997; 100: 2961–2969.
81.
FurmanR.R., AsgaryZ., MascarenhasJ.O.Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol.2000; 164: 2200–2206.
82.
HideshimaT., ChauhanD., RichardsonP.NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem.2002; 277: 16639–16647.
83.
ReutherJ.Y., ReutherG.W., CortezD.A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev.1998; 12: 968–981.
84.
MayoM.W., BaldwinA.S.The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta.2000; 1470: M55–M62.
85.
PahlH.L.Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene.1999; 18: 6853–6866.
86.
AdamsJ.Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med.2002; 8(4 suppl): S49–S54.
87.
GuzmanM.L., SwiderskiC.F., HowardD.S.Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A.2002; 99: 16220–16225.
88.
AdamsJ.The proteasome: structure, function, and role in the cell. Cancer Treat Rev.2003; 29(suppl 1): 3–9.
89.
LoweS.W., BodisS., McClatcheyA.p53 status and the efficacy of cancer therapy in vivo. Science.1994; 266: 807–810.
90.
LoweS.W., RuleyH.E., JacksT.p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell.1993; 74: 957–967.
91.
WierengaP.K., SetroikromoR., KampsG.Differences in heat sensitivity between normal and acute myeloid leukemic stem cells: feasibility of hyperthermic purging of leukemic cells from autologous stem cell grafts. Exp Hematol.2003; 31: 421–427.
